Scientists Discover ‘Novel Drug Target for Glioblastoma’

Monday, January 13, 2020 - 10:13

Researchers from Lerner Research Institute of Cleveland Clinic revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation.

According to the Healio report, Justin Lathia, PhD, vice chair of the department of cardiovascular and metabolic sciences at Lerner Research Institute of Cleveland Clinic, stated that, “these findings are exciting because they put forth a new paradigm for glioma stem cell regulation.”

“This pathway shows that glioma stem cells’ ability to access key nutrients in their surrounding microenvironment, by way of ADAMDEC1, is integral for their maintenance and spread. Finding a way to interrupt this feedback loop will be important for treating glioblastoma,” he said.

Previous research has shown that when the protein fibroblast growth factor 2 (FGF2) is active, it contributes to glioma stem cell self-renewal and tumor growth. However, researchers lacked understanding of how this process occurs.

For this reason, Lathia and colleagues sought to identify how glioblastoma cancer stem cells maintain their stemness. The researchers found FGF2 is a key intermediary in the multistep, pro-cancer signaling loop, and that “turning off” FGF2 potentially could prevent glioblastoma progression.


Popular News

Latest News